SAN DIEGO, March 2 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. , a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced it plans to report fourth quarter and annual 2009 financial results on Friday, March 12, 2010 before the open of the financial markets. The announcement will be followed by a conference call with the investment community at 8:00 a.m. PST, (11:00 a.m. EST) which will be simultaneously broadcast over the Internet. Management will discuss the financial results and highlights for the fourth quarter 2009 and provide a product pipeline update.
(Logo: http://www.newscom.com/cgi-bin/prnh/20100302/LA63139LOGO)
To participate by telephone please dial 888-256-9044 for domestic callers or 706-643-5585 for international callers and provide the conference ID # 60348512. Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of the company’s Web site at www.halozyme.com. Shortly after the call an audio replay will be available on Halozyme’s Web site for seven days. A telephone replay will be available by dialing 800-642-1687 from the U.S., or 706-645-9291 for international callers.
Halozyme management team members will also be presenting at upcoming investor conferences:
To listen to the audio webcast of the presentations live or after the event, please visit the company’s Web site at www.halozyme.com. Replays will be available for 30 days after the presentations.
About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company’s portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme’s Enhanze(TM) technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche to apply Enhanze technology to Roche’s biological therapeutics, including Herceptin(R), for up to 13 targets, and with Baxter BioScience to apply Enhanze technology to Baxter’s biological therapeutic compound, GAMMAGARD Liquid(R). The product candidates in Halozyme’s research pipeline target multiple areas of significant unmet medical need. For more information visit www.halozyme.com.
CONTACT: Robert H. Uhl, Senior Director, Investor Relations of Halozyme
Therapeutics, Inc., +1-858-704-8264, ruhl@halozyme.com
Web site: http://www.halozyme.com/
